Galić Zoran, Kitchen Scott G, Subramanian Aparna, Bristol Greg, Marsden Matthew D, Balamurugan Arumugam, Kacena Amelia, Yang Otto, Zack Jerome A
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, USA.
Stem Cells. 2009 Jan;27(1):100-7. doi: 10.1634/stemcells.2008-0813.
Human embryonic stem cells (hESC) have the potential to revolutionize certain medical treatments, including T-cell-based therapies. However, optimal approaches to develop T cells from hESC are lacking. In this report, we show that T-cell progenitors can be derived from hESC cultured as embryoid bodies (EBs). These EB-derived T-cell progenitors give rise to phenotypically and functionally normal cells of the T lineage when transferred into human thymic tissue implanted in immunocompromised mice, suggesting that introduction of these progenitors into patients may also yield functional T cells. Moreover, hematopoietic progenitors demonstrating T-cell potential appeared to be CD45+/CD34+, resembling those found in normal bone marrow. In contrast to T cells developed from hESC cocultured on murine stromal cells, the EB-derived T cells also expressed normal levels of CD45. Importantly, the EB system eliminates the previous need for murine cocultures, a key impediment to developing a protocol for T-cell progenitor derivation suitable for clinical use. Furthermore, following lentiviral-mediated introduction of a vector expressing enhanced green fluorescent protein into hESC, stable transgene expression was maintained throughout differentiation, suggesting a potential for gene therapy approaches aimed at the augmentation of T-cell function or treatment of T-cell disorders.
人类胚胎干细胞(hESC)有潜力彻底改变某些医学治疗方法,包括基于T细胞的疗法。然而,目前缺乏从hESC培养出T细胞的最佳方法。在本报告中,我们表明T细胞祖细胞可从作为胚状体(EB)培养的hESC中获得。当将这些源自EB的T细胞祖细胞转移到植入免疫缺陷小鼠体内的人胸腺组织中时,它们会产生表型和功能正常的T系细胞,这表明将这些祖细胞引入患者体内也可能产生功能性T细胞。此外,表现出T细胞潜能的造血祖细胞似乎是CD45+/CD34+,类似于在正常骨髓中发现的细胞。与在小鼠基质细胞上共培养的hESC发育而来的T细胞不同,源自EB的T细胞也表达正常水平的CD45。重要的是,EB系统消除了先前对小鼠共培养的需求,而小鼠共培养是开发适合临床使用的T细胞祖细胞衍生方案的关键障碍。此外,在通过慢病毒介导将表达增强型绿色荧光蛋白的载体引入hESC后,在整个分化过程中都维持了稳定的转基因表达,这表明针对增强T细胞功能或治疗T细胞疾病的基因治疗方法具有潜力。